Ph3 Chemo w/ or w/o INCB161734 in Previously Untreated KRAS G12D-Mutated Metastatic PDAC
Phase III Clinical Trial
A Randomized Double-Blind Phase 3 Study of Chemotherapy With orWithout INCB161734 in Previously Untreated KRAS G12D�MutatedMetastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)